Doctors need to be fully aware of the risk/benefit ratio whenprescribing for older people, and should do so only after the patient has been individually assessed for capacity to benefit from treatment, irrespective of age. Also, the need for medication should be reviewed at regular intervals, says the second edition of Medication for Older People, published by the UK Royal College of Physicians (Marketletter May 19).
The over-65s constitute 18% of the UK population but receive 45% of all prescription items, 78% of which are repeats, it says. They are potentially the greatest beneficiaries of appropriate, optimal drug therapy, but they also suffer much drug-related iatrogenic disease due to inappropriate treatment, eg incorrect medication, inappropriate polypharmacy and/or inadequate monitoring of therapy, particularly in continuing care. The study urges prescribers to think carefully, make every reasonable effort to establish an accurate diagnosis, consider if drug treatment is appropriate, not overprescribe, and review the need for repeat prescriptions regularly.
A thorough drug history should be taken before prescribing, including the patient's current medication, over-the-counter therapies, previous adverse drug reactions and social support to monitor compliance. If this seems incomplete, a collateral history should be taken from relatives, the general practitioner, primary care nurses etc.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze